Research Analysts Issue Forecasts for Immunome Q1 Earnings

Key Points

• HC Wainwright forecasts continued losses for Immunome in 2027, estimating EPS of ($0.72) in Q1, improving to ($0.60) in Q4, while maintaining a Buy rating.
• Immunome reported a quarterly loss of $0.76 per share, missing the consensus estimate of a $0.62 loss by $0.14.
• Analyst views are mostly positive: MarketBeat’s consensus is Moderate Buy with an average $33.85 price target, although Stifel cut its target to $23 and kept a Hold rating. Shares opened at $18.65, down 3.7%.

Immunome, Inc. (NASDAQ:IMNM - Free Report) - Investment analysts at HC Wainwright issued their Q1 2027 EPS estimates for Immunome in a report issued on Tuesday, November 10th. HC Wainwright analyst A. Maldonado forecasts that the company will post earnings per share of ($0.72) for the quarter. HC Wainwright currently has a "Buy" rating on the stock. The consensus estimate for Immunome's current full-year earnings is ($2.48) per share. HC Wainwright also issued estimates for Immunome's Q2 2027 earnings at ($0.70) EPS, Q3 2027 earnings at ($0.69) EPS and Q4 2027 earnings at ($0.60) EPS.

Immunome (NASDAQ:IMNM - Get Free Report) last announced its quarterly earnings results on Monday, November 9th. The company reported ($0.76) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.62) by ($0.14).

Several other brokerages have also recently weighed in on IMNM. Stifel Nicolaus lowered their target price on Immunome from $24.00 to $23.00 and set a "hold" rating for the company in a report on Tuesday. Piper Sandler decreased their price objective on Immunome from $33.00 to $30.00 and set an "overweight" rating for the company in a report on Tuesday. Alliance Global Partners began coverage on shares of Immunome in a research note on Monday, September 21st. They issued a "buy" rating and a $32.00 price objective for the company. Wedbush reaffirmed an "outperform" rating and issued a $35.00 price objective on shares of Immunome in a research note on Tuesday, October 27th. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Immunome in a report on Thursday, October 15th. Fourteen research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Immunome presently has a consensus rating of "Moderate Buy" and an average price target of $33.85.

Immunome Stock Down 3.7%

IMNM opened at $18.65 on Wednesday. The stock's fifty day moving average is $21.15 and its two-hundred day moving average is $22.33. The company has a market capitalization of $2.12 billion, a P/E ratio of -7.06 and a beta of 2.68. Immunome has a 52 week low of $16.11 and a 52 week high of $30.06.

Insider Activity at Immunome

In related news, insider Jack Higgins sold 13,200 shares of the company's stock in a transaction on Friday, September 11th. The stock was sold at an average price of $25.32, for a total transaction of $334,224.00. Following the completion of the sale, the insider directly owned 65,050 shares in the company, valued at $1,647,066. This represents a 16.87% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 7.21% of the company's stock.

Hedge Funds Weigh In On Immunome

Several institutional investors and hedge funds have recently added to or reduced their stakes in IMNM. BlackRock Inc. purchased a new stake in shares of Immunome during the second quarter valued at about $186,588,000. Wellington Management Group LLP raised its stake in shares of Immunome by 10.1% during the 2nd quarter. Wellington Management Group LLP now owns 5,210,216 shares of the company's stock worth $110,404,000 after acquiring an additional 478,239 shares in the last quarter. Primecap Management Co. CA bought a new position in shares of Immunome during the 2nd quarter worth approximately $97,081,000. Readystate Asset Management LP raised its stake in shares of Immunome by 23.3% during the 2nd quarter. Readystate Asset Management LP now owns 1,605,820 shares of the company's stock worth $34,027,000 after acquiring an additional 303,958 shares in the last quarter. Finally, Bank of America Corp DE lifted its position in Immunome by 285.6% during the first quarter. Bank of America Corp DE now owns 781,607 shares of the company's stock valued at $17,094,000 after acquiring an additional 578,890 shares during the last quarter. Hedge funds and other institutional investors own 44.58% of the company's stock.

More Immunome News

Here are the key news stories impacting Immunome this week:

• Positive Sentiment: HC Wainwright reiterated its Buy rating and forecast quarterly losses of $0.72, $0.70, $0.69 and $0.60 per share for Q1–Q4 2027, respectively. The forecasts indicate continued losses, but the Buy rating is supportive.
• Positive Sentiment: Piper Sandler maintained an Overweight rating and a $30 price target, despite lowering it from $33. Piper Sandler ratings
• Neutral Sentiment: Immunome released its third-quarter results and a business update; the supplied coverage does not detail the update’s contents. Immunome third-quarter results and business update
• Negative Sentiment: Immunome reported a third-quarter loss of $0.76 per share, missing the consensus estimate of a $0.62 loss by $0.14 per share. Immunome earnings press release
• Negative Sentiment: Stifel Nicolaus lowered its price target from $24 to $23 and kept a Hold rating, signaling less upside in its view. Stifel Nicolaus ratings

About Immunome

Immunome is a biotechnology company focused on discovering and developing therapies for cancer. It uses an antibody-discovery platform to identify targets and develop medicines intended to address areas of significant unmet medical need. The company's research and development programs include targeted cancer treatments, such as antibody-based therapies and other drug candidates. Its portfolio has included investigational medicines for solid tumors and other cancers; these products are in development and are not necessarily approved for commercial use.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.